Phospholipid-stabilized mesoporous carbon nanospheres as versatile carriers for systemic delivery of amphiphobic SNX-2112 (a Hsp90 inhibitor) with enhanced antitumor effect

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 94, Issue , 2015, Pages 30-41

  Zhang, Xingwang ^a   Zhang, Tianpeng ^a   Ye, Yanghuan ^a   Chen, Huaqing ^a   Sun, Hua ^a   Zhou, Xiaotong ^a   Ma, Zhiguo ^a   Wu, Baojian ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Amphiphobic; Antitumor effect; Breast cancer; Mesoporous carbon; SNX 2112

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON; CLATHRIN; HEAT SHOCK PROTEIN 90 INHIBITOR; NANOSPHERE; PHOSPHOLIPID; SNX 2112; UNCLASSIFIED DRUG; DRUG CARRIER; FUSED HETEROCYCLIC RINGS; GLUCOSE TRANSPORTER; HEAT SHOCK PROTEIN 90; NANOCONJUGATE;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CELL; CAVEOLA; CELL MIGRATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; ELECTRON SPIN RESONANCE; ENDOCYTOSIS; FEMALE; IN VITRO STUDY; INTERNALIZATION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PARTICLE SIZE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; ADSORPTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HEPG2 CELL LINE; HUMAN; MCF 7 CELL LINE; MEDICINAL CHEMISTRY; METABOLISM; NANOMEDICINE; PATHOLOGY; PHARMACEUTICS; POROSITY; PROCEDURES; SOLUBILITY; TISSUE DISTRIBUTION; TUMOR VOLUME;

ADSORPTION; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBON; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; ENDOCYTOSIS; FEMALE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HEP G2 CELLS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MCF-7 CELLS; MICE, INBRED BALB C; NANOCONJUGATES; NANOMEDICINE; PHOSPHOLIPIDS; POROSITY; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929323233     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.04.023     Document Type: Article

References (35)

1. L. Di, P.V. Fish, and T. Mano Bridging solubility between drug discovery and development Drug Discov. Today 17 2012 486 495
2. P.R. Ravi, N. Aditya, H. Kathuria, S. Malekar, and R. Vats Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism Eur. J. Pharm. Biopharm. 87 2014 114 124
3. C. Nehate, S. Jain, A. Saneja, V. Khare, N. Alam, R. Dubey, and P.N. Gupta Paclitaxel formulations: challenges and novel delivery options Curr. Drug Deliv. 11 2014 666 686
4. S. Huang, R. Fang, J. Xu, S. Qiu, H. Zhang, J. Du, and S. Cai Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug J. Drug Target. 19 2011 487 496
5. V.W. Fung, G.N. Chiu, and L.D. Mayer Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumors Biochim. Biophys. Acta 1611 2003 63 69
6. V. Saxena, and M.D. Hussain Polymeric mixed micelles for delivery of curcumin to multidrug resistant ovarian cancer J. Biomed. Nanotechnol. 9 2013 1146 1154
7. Z. Wang, G. Niu, and X. Chen Polymeric materials for theranostic applications Pharm. Res. 31 2014 1358 1376
8. J. Zheng, Y. Wan, A. Elhissi, Z. Zhang, and X. Sun Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles Pharm. Res. 31 2014 2220 2233
9. Y. Ye, X. Zhang, T. Zhang, H. Wang, and B. Wu Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique Drug Dev. Ind. Pharm. 2014 10.3109/03639045.2014.95458
10. W. Li, Q. Yue, Y. Deng, and D. Zhao Ordered mesoporous materials based on interfacial assembly and engineering Adv. Mater. 25 2013 5129 5152
11. S.C. Shen, W.K. Ng, L.S. Chia, Y.C. Dong, and R.B. Tan Applications of mesoporous materials as excipients for innovative drug delivery and formulation Curr. Pharm. Des. 19 2013 6270 6289
12. D. Saha, K.E. Warren, and A.K. Naskar Soft-templated mesoporous carbons as potential materials for oral drug delivery Carbon 71 2014 47 57
13. M.F. Gencoglu, A. Spurri, M. Franko, J. Chen, D.K. Hensley, C.L. Heldt, and D. Saha Biocompatibility of soft-templated mesoporous carbons ACS Appl. Mater. Interf. 6 2014 15068 15077
14. J. Gu, S. Su, Y. Li, Q. He, and J. Shi Hydrophilic mesoporous carbon nanoparticles as carriers for sustained release of hydrophobic anti-cancer drugs Chem. Commun. 47 2011 2101 2103
15. Y. Fang, D. Gu, Y. Zou, Z.X. Wu, F.Y. Li, R.C. Che, Y.H. Deng, B. Tu, and D.Y. Zhao A low-concentration hydrothermal synthesis of biocompatible ordered mesoporous carbon nanospheres with tunable and uniform size Angew. Chem. Int. Ed. 49 2010 7987 7991
16. R.J. Gillies, I. Robey, and R.A. Gatenby Causes and consequences of increased glucose metabolism of cancers J. Nucl. Med. 49 Suppl. 2 2008 24S 42S
17. K.K. Chan, J.Y. Chan, K.K. Chung, and K.P. Fung Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5 J. Cell. Biochem. 93 2004 1134 1142
18. K.S. Liu, H. Liu, J.H. Qi, Q.Y. Liu, Z. Liu, M. Xia, G.W. Xing, S.X. Wang, and Y.F. Wang SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells Cancer Lett. 318 2012 180 188
19. B. Chang, D. Guan, Y. Tian, Z. Yang, and X. Dong Convenient synthesis of porous carbon nanospheres with tunable pore structure and excellent adsorption capacity J. Hazard. Mater. 262 2013 256 264
20. Y.H. Tan, J.A. Davis, K. Fujikawa, N.V. Ganesh, A.V. Demchenko, and K.J. Stine Surface area and pore size characteristics of nanoporous gold subjected to thermal, mechanical, or surface modification studied using gas adsorption isotherms, cyclic voltammetry, thermogravimetric analysis, and scanning electron microscopy J. Mater. Chem. 22 2012 6733 6745
21. L.M. Bareford, B.R. Avaritt, H. Ghandehari, A. Nan, and P.W. Swaan Riboflavin-targeted polymer conjugates for breast tumor delivery Pharm. Res. 30 2013 1799 1812
22. W. Liu, H. Liu, H. Sun, D. Dong, Z. Ma, Y. Wang, and B. Wu Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS) Xenobiotica 44 2014 455 464
23. Z.H. Hu, M.P. Srinivasan, and Y.M. Ni Novel activation process for preparing highly microporous and mesoporous activated carbons Carbon 39 2001 877 886
24. J. Rouquerol, D. Avnir, C.W. Fairbridge, D.H. Everett, J.M. Haynes, N. Pernicone, J.D.F. Ramsay, K.S.W. Sing, and K.K. Unger Recommendations for the characterization of porous solids (Technical Report) Pure Appl. Chem. 66 1994 1739 1758
25. S.H. Kang, H.J. Cho, G. Shim, S. Lee, S.H. Kim, H.G. Choi, C.W. Kim, and Y.K. Oh Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy Pharm. Res. 28 2011 3069 3078
26. R.B. Selvi, S. Chatterjee, D. Jagadeesan, P. Chaturbedy, B.S. Suma, M. Eswaramoorthy, and T.K. Kundu ATP driven clathrin dependent entry of carbon nanospheres prefer cells with glucose receptors J. Nanobiotechnol. 10 2012 1 9
27. F. Zhao, Y. Zhao, Y. Liu, X. Chang, C. Chen, and Y. Zhao Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials Small 7 2011 1322 1337
28. T.-G. Iversen, T. Skotland, and K. Sandvig Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies Nano Today 6 2011 176 185
29. X. Zhang, J. Qi, Y. Lu, W. He, X. Li, and W. Wu Biotinylated liposomes as potential carriers for the oral delivery of insulin Nanomedicine 10 2014 167 176
30. J.P. Wood, T. Mammone, G. Chidlow, T. Greenwell, and R.J. Casson Mitochondrial inhibition in rat retinal cell cultures as a model of metabolic compromise: mechanisms of injury and neuroprotection Invest. Ophthalmol. Vis. Sci. 53 2012 4897 4909
31. N.T. Huynh, M. Morille, J. Bejaud, P. Legras, A. Vessieres, G. Jaouen, J.P. Benoit, and C. Passirani Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect Pharm. Res. 28 2011 3189 3198
32. Y. Qin, W. Fan, H. Chen, N. Yao, W. Tang, J. Tang, W. Yuan, R. Kuai, Z. Zhang, Y. Wu, and Q. He In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes J. Drug Target. 18 2010 536 549
33. B.A. Pulaski, and S. Ostrand-Rosenberg Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines Cancer Res. 58 1998 1486 1493
34. C.J. Aslakson, and F.R. Miller Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor Cancer Res. 52 1992 1399 1405
35. S.J. Choi, and J.H. Choy Layered double hydroxide nanoparticles as target-specific delivery carriers: uptake mechanism and toxicity Nanomedicine (Lond) 6 2011 803 814